

# Vilanterol (trifenatate)

# Catalog No: tcsc1679

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

**Size:** 100mg

Specifications

CAS No:

503070-58-4

Formula:

 $C_{44}H_{49}CI_2NO_7$ 

**Pathway:** GPCR/G Protein

**Target:** Adrenergic Receptor

#### Purity / Grade:

>98%

#### Solubility:

H2O :

#### Alternative Names:

GW642444M

### **Observed Molecular Weight:**

774.77

Copyright 2021 Taiclone Biotech Corp.




## **Product Description**

Vilanterol trifenatate is a long-acting  $\beta_2$ -adrenoceptor ( $\beta_2$ -AR) agonist with 24 h activity. The **pEC**<sub>50</sub>s for  $\beta_2$ -AR, $\beta_1$ -AR and  $\beta_3$ -AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.

IC50 & Target: pEC50: 10.37±0.05 ( $\beta_2$ -adrenoceptor), 6.98±0.03 ( $\beta_1$ -adrenoceptor), 7.36±0.03 ( $\beta_3$ -adrenoceptor)<sup>[1]</sup>

In Vitro: The selectivity of Vilanterol trifenatate for  $\beta_2$ -AR over the other  $\beta$ -AR receptor subtypes ( $\beta_2$  and  $\beta_3$ ) is established by testing the ability of Vilanterol to elicit concentration-dependent increases in cAMP in CHO cells expressing human  $\beta_1^-$ ,  $\beta_2^-$ , and  $\beta_3^-$  AR. Vilanterol is demonstrated to be highly selective for the  $\beta_2$ -AR with at least a 1000-fold selectivity over both  $\beta_2^-$  and  $\beta_3^-$ AR subtypes. This analysis results in a low-affinity pK<sub>D</sub> for [<sup>3</sup>H]Vilanterol of 9.44±0.07 (n=4) in the presence Gpp(NH)p and a high-affinity pK<sub>D</sub> of 10.82±0.12 (n=4) and a low-affinity pK<sub>D</sub> 9.47±0.17 (n=4) in the absence of Gpp(NH)p. In addition, a low-affinity pK<sub>D</sub> for [<sup>3</sup>H]Vilanterol of 9.52±0.24 (n=4) in the absence of Gpp(NH)p (37°C) is observed<sup>[1]</sup>. Vilanterol trifenatate is a novel inhaled long-acting  $\beta_2$ -agonist with inherent 24 h activity in vitro in development as a combination with the inhaled corticosteroid fluticasone furoate for both COPD and asthma<sup>[2]</sup>. Vilanterol is a novel long-acting  $\beta_2$ -agonist (LABA) with inherent 24-hour activity for once-daily clinical treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with the inhaled novel corticosteroid fluticasone furoate, also active for 24 hours<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.